ITI-1549

ITI-1549
Clinical data
Other namesITI1549
Routes of
administration		Unspecified[1]
Drug classNon-hallucinogenic serotonin 5-HT2A receptor agonist[2][3]

ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist which is under development for the treatment of mood disorders and other psychiatric disorders.[1][4][5][2][3] In addition to acting at the serotonin 5-HT2A receptor, it is also an antagonist of the serotonin 5-HT2B receptor and an agonist of the serotonin 5-HT2C receptor.[3][6] The drug's route of administration has not been specified.[1]

  1. ^ a b c "ITI 1549". AdisInsight. 15 January 2024. Retrieved 23 October 2024.
  2. ^ a b Intra-Cellular Therapies (22 February 2024). "Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update". GlobeNewswire News Room. Retrieved 23 October 2024. ITI-1500 Non-Hallucinogenic Psychedelic Program: In 2023, we introduced the ITI-1500 program. This program is focused on the development of novel non-hallucinogenic psychedelics for the treatment of mood, anxiety and other neuropsychiatric disorders without the liabilities of known psychedelics, including the hallucinogenic potential and risk for cardiac valvular pathologies. Our lead product candidate in this program, ITI-1549, is advancing through IND enabling studies and is expected to enter human testing in late 2024 or early 2025.
  3. ^ a b c Davis R, Dutheil SS, Zhang L, Lehmann E, Awadallah N, Yao W, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P358. Discovery and Characterization of ITI-1549, a Novel Non-Hallucinogenic Psychedelic for the Treatment of Neuropsychiatric Disorders". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (272–273). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
  4. ^ "Delving into the Latest Updates on ITI-1549 with Synapse". Synapse. 12 October 2024. Retrieved 23 October 2024.
  5. ^ "Pipeline". Intracellular Therapies. Retrieved 23 October 2024. Pipeline: [...] ITI-1500 Series: ITI-1549 – Mood and Other Neuropsychiatric Disorders [...] ITI-1500 series is our portfolio of Non-Hallucinogenic Psychedelics. ITI-1549 is our lead product candidate in this program.
  6. ^ Cite error: The named reference WO2024145659A1 was invoked but never defined (see the help page).